Status:
UNKNOWN
Assessment of Sleep Quality in Cannabinoid Therapy
Lead Sponsor:
Cerebra Medical
Collaborating Sponsors:
Ekosi Health Centre
Conditions:
Poor Sleep Quality
Eligibility:
All Genders
40-65 years
Brief Summary
The current study aims to assess the impact of starting cannabinoid therapy on sleep quality for individuals with sleep disturbance.
Detailed Description
After the initial signing of the consent form, they will complete a battery of baseline questionnaires online on sleep, including the Sleep Regularity Questionnaire, Epworth Sleepiness Scale, Insomnia...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- A Pittsburgh Sleep Quality Index score \>5
- Between the ages of 40-65
- No current recreational or medical cannabis use within 4 weeks of the study initiation OR positive urine drug screen (UDS) for Tetrahydrocannabinol
- No use of anti-psychotics, tricyclic antidepressants, or prescription stimulants
- No use of medications for promoting sleep (e.g., anti-histamines, benzodiazepines, melatonin).
- Low risk of Obstructive Sleep Apnea (Low Risk on Berlin Questionnaire), or no presence of moderate or severe Obstructive Sleep Apnea on baseline polysomnography (AHI \<15).
- Has been prescribed THC:CBD combination therapy
Exclusion
Key Trial Info
Start Date :
August 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05237037
Start Date
August 22 2022
End Date
August 1 2023
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ekosi Health Centre
Winnipeg, Manitoba, Canada, R3A 0J5